Article
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy - 1 Mar 2003
Zhao Xilin, Eisner William, Perl-Rosenthal Nathan, Kreiswirth Barry, Drlica Karl
Abstract excerpt
The new quinolone garenoxacin (BMS-284756), which lacks a C-6 fluorine, was examined for its ability to block the growth of Staphylococcus aureus. Measurement of the MIC and the mutant prevention concentration (MPC) revealed that garenoxacin was 20-fold more potent than ciprofloxacin for a variety of ciprofloxacin-susceptible isolates, some of which were resistant to methicillin. The MPC for 90% of the isolates...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
